VINCRISTINE AND PREDNISONE VS VINCRISTINE, L-ASPARAGINASE, AND PREDNISONE FOR 2ND REMISSION INDUCTION OF ACUTE LYMPHOCYTIC-LEUKEMIA IN CHILDREN

被引：12

作者：

HERSON, J

STARLING, KA

DYMENT, PG

HUMPHREY, GB

PULLEN, J

VATS, T

机构：

[1] M.D. Anderson Hospital and Tumor Institute, University of Texas System Cancer Center, Houston

[2] Texas Children's Hospital, Baylor College of Medicine, Houston

[3] Cleveland Clinic Foundation, Cleveland

[4] Children's Memorial Hospital, University of Oklahoma, Oklahoma City

[5] Children's Hospital, University of Mississippi, Jackson

[6] University of Kansas Medical Center, Kansas City

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1979年 / 6卷 / 04期

关键词：

acute lymphocytic leukemia; pediatric acute leukemia; second remission induction; vincristine + L‐asparaginase + prednisone; vincristine + prednisone;

D O I：

10.1002/mpo.2950060408

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Second remission induction rates for vincristine and prednisone alone (VP) and vincristine, L‐asparaginase, and prednisone (VLP) are compared for children with acute lymphocytic leukemia. No evidence of a significant difference between the second induction complete remission rate for VP (78.6%) and VLP (73.7%) was found. Duration of first remission and prognostic group at initial diagnosis (defined on the basis of age and white blood count at initial diagnosis) are shown to be significant prognostic factors for second remission induction; and three second remission induction risk groups are defined on the basis of these two factors. Periodic reinforcement with prednisone in first remission does not appear to lower second induction complete response (CR) rates for VP. There was no evidence of a significant difference in the frequency of occurrence of severe toxicity between the VP and VLP regimens. Copyright © 1979 Wiley‐Liss, Inc., A Wiley Company

引用

页码：317 / 323

页数：7

共 9 条

[1]

Lane DM, Haggard ME, Lonsdale D, Et al., Remission induction in childhood leukemia with second course vincristine (NSC‐675740) and prednisone (NSC‐10023) therapy, Cancer Chemother Rep, 54, pp. 113-118, (1970)

[2]

Starling KA, Lane DM, Sutow WW, Et al., Third and fourth remission induction with prednisone (NSC‐10023) and vincristine (NSC‐67574) in children with acute leukemia, Cancer Chemother Rep, 54, pp. 293-294, (1970)

[3]

Sutow WW, Garcia F, Starling KA, Et al., L‐asparaginase therapy in children with advanced leukemia, Cancer, 28, pp. 819-824, (1971)

[4]

Land VJ, Sutow WW, Fernbach DJ, Et al., Toxicity of L‐asparaginase in children with advanced leukemia, Cancer, 30, pp. 339-347, (1972)

[5]

Rausen AR, Glidwell OJ, (1970)

[6]

Hewlett JS, Battle JD, Bishop RC, Et al., Phase II study of A‐8103 (NSC‐25154) in acute leukemia in adults. Appendix: Criteria for evaluating chemotherapy in acute leukemia, Cancer Chemother Rep, 42, pp. 25-28, (1964)

[7]

George SL, Fernbach DJ, Vietti TJ, Et al., Factors influencing survival in pediatric acute leukemia. The SWCCSG experience: 1958–1970, Cancer, 32, pp. 1542-1555, (1973)

[8]

Lee ET, A computer program for linear logistic regression analysis, Comput Programs in Biomed, 4, pp. 80-92, (1974)

[9]

Fleiss J, Statistical Methods for Rates and Proportions, (1973)

← 1 →